According to the official website of the US House Rules Committee, etc., the revised US “Biosafety Act” has been incorporated into the latest version of the 2026 Defense Authorization Act, which stipulates that US federal agencies will be prohibited from signing contracts with “concerned biotechnology companies.” Unlike last year's multiple versions directly naming pharmaceutical companies such as Pharmaceutical and Kangde, this year's revised bill does not specifically name any companies, but stipulates that in the future, the White House Administration and Budget Office will draw up a list of restricted companies within one year after the bill is passed, referring to relevant lists from the US Department of Defense and others. The US House Rules Committee will meet on December 10 at 5 p.m. Beijing time to discuss the 2026 NDAA, which includes the bill.

According to the official website of the US House Rules Committee, etc., the revised US “Biosafety Act” has been incorporated into the latest version of the 2026 Defense Authorization Act, which stipulates that US federal agencies will be prohibited from signing contracts with “concerned biotechnology companies.” Unlike last year's multiple versions directly naming pharmaceutical companies such as Pharmaceutical and Kangde, this year's revised bill does not specifically name any companies, but stipulates that in the future, the White House Administration and Budget Office will draw up a list of restricted companies within one year after the bill is passed, referring to relevant lists from the US Department of Defense and others. The US House Rules Committee will meet on December 10 at 5 p.m. Beijing time to discuss the 2026 NDAA, which includes the bill.